Abbott, Fujirebio Co-Developing HE4/CA125 Dx to Improve Early Ovarian Cancer Detection

By combining HE4 with CA125 detection capabilities in a single test, Abbott is hoping to improve doctors' ability to identify women at risk for ovarian cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.